Messaging Strategies + Financial Incentive for Lung Cancer Screening Eligibility

Recruiting in Palo Alto (17 mi)

Overseen by Katharine A Rendle, PhD,MSW,MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center at Penn Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Eligibility Criteria

This trial is for people aged 50-80 who've had a primary care visit at Penn Medicine between 2020-2025 and are eligible for lung cancer screening. It's not for those with a history of lung cancer, who've completed lung cancer screening at Penn Medicine, or don't want to be contacted for research.

Inclusion Criteria

Have completed at least one primary care visit at Penn Medicine in 2020-2025

I am between 50 and 80 years old.

Exclusion Criteria

Do not otherwise meet inclusion criteria

I have a documented history of lung cancer.

I do not wish to be contacted for research purposes.

Participant Groups

The study is testing how different types of messages affect the response rates to a survey estimating eligibility for lung cancer screening. The goal is to find the most effective messaging strategy to encourage participation in future screenings.

Group I: Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (CA) plus an incentive

Group II: Arm 8 (Introductory Message B + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (BB)

Group III: Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (BB) plus an incentive

Group IV: Arm 6 (Introductory Message B + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed messages (BA)

Group V: Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (BA) plus an incentive

Group VI: Arm 4 (Introductory Message A + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (AB)

Group VII: Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (AB) plus an incentive

Group VIII: Arm 2 (Introductory Message A + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed messages (AA)

Group IX: Arm 12 (Introductory Message C + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (CB)

Group X: Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (CB) plus an incentive

Group XI: Arm 10 (Introductory Message C + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed message (CA)

Group XII: Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (AA) plus an incentive

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Pennsylvania Philadelphia, PA

Who Is Running the Clinical Trial?

Abramson Cancer Center at Penn Medicine Lead Sponsor

National Cancer Institute (NCI) Collaborator

National Institutes of Health (NIH) Collaborator

References